Home · Evidence

Five Human Studies at a Glance

Judy 2003, Fukushima and Miura 2012, Lopez-Murillo 2022, Hibi 2022 and Hussain 2022: five published trials summarized with participant numbers, dosage, duration and measured outcomes.

Clinical evidence

What the human studies actually found

Sample sizes, doses, durations and outcomes are quoted exactly as published — nothing rounded up, nothing dressed up.

StudySubjectsDose · DurationKey result
Judy et al., 2003n=10 people with type 2 diabetes (56 volunteers screened, 32 eligible, 10 enrolled; soft gel n=5, hard gel n=5)Glucosol (Banaba standardised to 1% Corosolic acid) 16–48 mg/day for 15 days, with a 10-day wash-out between dosesA dose-dependent reduction in blood glucose, the largest being about 30% at the 48 mg dose. Reductions after 15 days were 4.9 / 10.7 / 30.0% for the soft gel and 3.18 / 6.5 / 20.2% for the hard gel at 16 / 32 / 48 mg respectively.
Fukushima et al. (cited in Miura, 2012)n=3110 mg Corosolic acid taken before a 75 g oral glucose tolerance testSignificantly lower blood glucose between the 60 and 120 minute time points.
Lopez-Murillo et al., 2022n=24 with metabolic syndromeBanaba 500 mg twice daily for 12 weeksImproved post-meal glucose, insulin and C-peptide; 67% of participants met the criteria for remission of metabolic syndrome; reduced hepatic insulin resistance.
Hibi et al., 2022n=14 with impaired glucose metabolism; randomised, double-blind, placebo-controlled, crossover designCorosolic acid 1 mg/day for 14 daysSignificantly lower glucose iAUC during the OGTT than placebo; Corosolic acid was lower than placebo at 30 minutes for glucose (p = 0.024) and at 120 minutes for insulin (p < 0.05).
Hussain et al., 2022Metformin + Ginkgo n=27 versus metformin + placebo n=20Ginkgo Biloba added to metformin for 90 daysImprovements in HbA1c, fasting serum glucose (FSG), serum insulin, the IRI index, BMI, lipid profile and inflammatory markers.

💡 Key takeaways

  • Banaba's effect on post-meal glucose has been observed at a dose as low as 1 mg of Corosolic acid per day, in a randomised, double-blind, placebo-controlled crossover trial.
  • Ginkgo Biloba was studied as an addition to standard medication, and the benefits reported were antioxidant, metabolic and vascular — not a direct glucose-lowering action of its own.
  • These are small, early-stage human studies. This product is a health functional food with a supporting role: it does not treat or cure disease, and it does not replace the medication your doctor has prescribed.